Summary of Conference Call Records Company Overview - The company discussed is 康希诺 (CanSino Biologics), a biopharmaceutical company focused on vaccine development and production. Key Points Financial Performance - For the year 2025, the company reported an operating revenue of 1.068 billion yuan, representing a year-on-year increase of 26.18% [1] - The net profit attributable to the parent company is 28 million yuan, marking a turnaround from previous losses [1][3] Sales and Product Development - The company has been actively building sales channels, with the main product, the MCV4 series, showing consistent revenue growth [1][3] - The PCV13 vaccine was approved for domestic sale in June 2025, expected to contribute to revenue growth in 2026 [1][3] Cost Management and Efficiency - The company has been focusing on cost reduction and efficiency improvement, leading to significant enhancements in operational efficiency [2][4] Research and Development Pipeline - The R&D pipeline is robust, with several products at various stages of development: - MCV4 for ages 4-6 was approved in February 2026 [4] - Vaccines for infants, including the DTPa-Hib-MCV4 combination, are under review for market approval [4] - The restructured polio vaccine is in Phase I clinical trials overseas and has received domestic clinical approval [4] - The DTcP-Hib-MCV4 combination vaccine has entered Phase I clinical trials [4] - The PCV24 vaccine has been approved for domestic clinical trials [4] - Positive results from Phase I trials of the recombinant pneumococcal protein vaccine (PBPV) are anticipated [4] mRNA Technology Development - The company is advancing mRNA technology, with ongoing development of mRNA vaccines for glioblastoma and rhabdomyosarcoma [4] - A new lipid nanoparticle delivery system (ISL-3C-LNP) has been developed and licensed out, with expectations for further advancements [4] International Market Expansion - The company has gained valuable experience in international market access, successfully entering the Indonesian market with MCV4, which is expected to lead to significant overseas revenue [4] - A project funding agreement has been signed with the Bill & Melinda Gates Foundation, ensuring continued financial support for projects [4] Global Product Strategy - The company is exploring the feasibility of market access and overseas collaborations for innovative global products within its pipeline [5]

Core Viewpoint - The report outlines the environmental, social, and governance (ESG) practices and performance of CanSino Biologics, emphasizing its commitment to sustainable development and social responsibility in various operational areas. Group 1: ESG Management and Governance - CanSino Biologics has established an ESG management system that integrates ESG principles into its core strategy, focusing on green development, product responsibility, value creation, and strong governance [4][5]. - The board of directors oversees the ESG management work, ensuring effective risk management and regular reviews of ESG goals [4][5]. - An ESG working group has been set up to coordinate the implementation of ESG policies across departments [4][5]. Group 2: Environmental Initiatives - The company adheres to a green low-carbon development model, optimizing production management to reduce emissions and energy consumption [4][5]. - CanSino Biologics is committed to achieving national carbon peak and carbon neutrality goals, actively responding to climate change [5][6]. Group 3: Social Responsibility and Community Engagement - CanSino Biologics has contributed approximately 447,700 RMB to various public welfare projects, focusing on healthcare and education [6]. - The company emphasizes employee rights and welfare, aiming to create a diverse and inclusive work environment, with a female employee ratio of 51.40% in 2024 [6][8]. Group 4: Product Development and Innovation - CanSino Biologics is dedicated to the research and development of innovative vaccines, utilizing advanced technologies such as virus-like particle (VLP) technology and mRNA platforms [10][11]. - The company has successfully developed multiple vaccines targeting various diseases, including a recombinant polio vaccine and a COVID-19 vaccine recognized by the WHO [10][11]. Group 5: Compliance and Ethical Standards - The company maintains a strong focus on compliance and ethical business practices, implementing a dual compliance system to ensure adherence to legal and ethical standards [5][6]. - CanSino Biologics has established a transparent and responsible supply chain management system, promoting integrity and sustainability [5][6].